Trial Profile

Phase IV Clinical Trial of Immunogenicity of ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a Population Aged 6 to 23 Months

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 10 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
Indications Meningococcal infections
Focus Adverse reactions; Pharmacodynamics
Acronyms CRM197 Vector
Sponsors Tianjin CanSino Biotechnology

Most Recent Events

04 Mar 2026 The protocol has been amended to addition in safety endpoint and treatment arm.
04 Mar 2026 Planned End Date changed from 31 Jan 2025 to 15 Jul 2026.
04 Mar 2026 Planned primary completion date changed from 1 Mar 2024 to 15 May 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com